Awards Nomination 20+ Million Readerbase
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Journal Flyer
Journal of Bioequivalence & Bioavailability
A bioequivalence study of two finofibrate tablet formulations in indian healthy subjects
4th World Congress on Bioavailability and Bioequivalence: Pharmaceutical R&D Summit
May 20-22, 2013 DoubleTree by Hilton, Beijing, China

Gaikwad NJ, Wagh N, Amit Bhople and Anup Thakre

Scientific Tracks Abstracts: J Bioequiv Availab

Abstract:

ormulation. Method: Randomized, single dose, open-label, three-treatment, three-period, three-sequence, crossover design under fasting period with 9 days wash out period was evaluated in 18 subjects. For the analysis of pharmacokinetic properties, the blood samples were taken up to 72 hours after dosing. Plasma concentration of Finofibrate was determined using High Performance Liquid Chromatography (HPLC) - Mass Spectrometry method. Pharmacokinetic parameters AUC 0-t , AUC 0-∞ and C max were tested for bioequivalence after log-transformation of data and ratios of t max were evaluated. Result: The point estimates and 90% confidence intervals (CI) Avs. C for C max , AUC 0-t and AUC 0-∞ , for Finofibrate were 62.84%, 85.03%, 86.34% respectively. The point estimates and 90% confidence intervals (CI) Bvs. C for C max , AUC 0-t and AUC 0-∞ , for Finofibrate were 82.89%, 95.87% and 96.63% respectively. Conclusion: Based on clinical, pharmacokinetic and statistical data obtained from 18 healthy adult male human subjects under fasting conditions, it may be concluded that a single dose of test formulation of drug ?Finofibrate? 145 mg tablet manufactured by Wockhardt Limited, India does not meet bioequivalence criteria of 80% to 125% for C max , AUC o-t and AUC 0-∞ when compared with reference formulation 145 mg Finofibrate??Tablet

Biography :

N.J.Gaikwad has awarded Ph.D. in 1988 from Nagpur University and working as Professor in Department of Pharmaceutical Sciences, RTM Nagpur University. He has teaching and research experience of 34 years. He supervised 4 All India Council for Technical Education major project as a Principal Investigator, published 30 research papers in reputed journals and also published 4 books in Pharmacy. He guided 21 Doctoral and 44 Post-graduate students, chief Coordinator in International Conference on Brain Research organized by International Brain Research Organization, Switzerland. He act Board of Governer in National Education and research, Govt. of India, Director in Hindustan Organic Chemical Limited, Mumbai, Zim Lab.Ltd.,Kalmeshwar, Unijules Nagpur.He is associated with various professional and Social organization.